# Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)

> **NCT05514444** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 64 (actual)

## Conditions studied

- Advanced/Metastatic Solid Tumors
- Neoplasms

## Interventions

- **BIOLOGICAL:** MK-4464
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** 89Zr-MK-4464

## Key facts

- **NCT ID:** NCT05514444
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-25
- **Primary completion:** 2025-09-18
- **Final completion:** 2025-09-18
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05514444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05514444, "Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05514444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*